ARS Pharmaceuticals, Inc. SPRY Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $98.99M+1.9% | $84.28M-5.5% | $142.77M+5,460% | $112.34M+22,368% | $97.12M+971,120% | ||
| $14.57M-15.8% | $13.18M-32.7% | $12.77M-36.0% | $14.44M-22.1% | $17.3M-8.7% | ||
| $261.22M+149% | $230.12M+221% | $205.66M+378% | $150.19M+288% | $104.82M— | ||
| $301.4M+143% | $263.73M+186% | $233.56M+270% | $171.68M+200% | $124.19M+100% | ||
| $301.4M+143% | $263.73M+186% | $233.56M+270% | $171.68M+200% | $124.19M+100% | ||
| -$202.42M— | -$179.45M— | —— | —— | —— | ||
| -204.5%— | -212.9%— | —— | —— | —— | ||
| $4.36M-62.8% | $8.07M-29.0% | $11.03M-3.2% | $11.61M-2.4% | $11.71M-4.9% | ||
| —— | -$171.38M-2,168% | -$126.46M-1,614% | -$81.55M-254% | -$36.63M+5.4% | ||
| —— | -$80K-128% | $12K-94.4% | $104K-27.8% | $196K+172% | ||
| -$197.98M-1,165% | -$171.3M-2,242% | -$80.04M-63.0% | -$48.02M-7.1% | -$15.65M+68.5% | ||
| -200%-184pp | -203.3%-212pp | -56.1%+1,856pp | -42.7%+8,926pp | -16.1%+496,944pp | ||
| -$2.01-1,082% | -$1.75-2,600% | -$0.82-60.8% | -$0.50-6.4% | -$0.17+67.3% | ||
| -$2.01-1,082% | -$1.75-2,600% | -$0.82-60.8% | -$0.50-6.4% | -$0.17+67.3% | ||
| 395M+0.2% | 393.8M+0.3% | 397.6M+3.1% | 395.8M+3.1% | 394.3M+3.2% | ||
| 395M+1.6% | 393.8M+1.7% | 392.2M+1.7% | 390.4M+1.6% | 388.9M+1.7% | ||
| $25.62M+1,137% | $20.42M+1,990% | $15.13M+13,413% | $7.06M— | $2.07M— | ||
| -$198.14M-1,182% | -$171.39M-2,198% | -$80.39M-65.4% | -$47.92M-6.9% | -$15.45M+69.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $11.76M— | ||
| $4.36M-62.8% | $8.07M-29.0% | $11.03M-3.2% | $11.61M-2.4% | $11.71M-4.9% | ||
| $98.99M+1.9% | $84.28M-5.5% | $142.77M+5,460% | $112.34M+22,368% | $97.12M+971,120% | ||
| -$202.42M-180% | -$179.45M-272% | -$135.91M-125% | -$104.47M-84.1% | -$72.19M-16.4% | ||
| -$200.93M-180% | -$178.08M-270% | -$134.93M-123% | -$103.86M-83.3% | -$71.85M-16.0% | ||
| -$200.93M-180% | -$178.08M-270% | -$134.93M-123% | -$103.86M-83.3% | -$71.85M-16.0% | ||
| -203%-129pp | -211.3%-157pp | -94.5%+2,259pp | -92.5%+11,242pp | -74%+619,276pp | ||
| -$202.42M-180% | -$179.45M-272% | -$135.91M-125% | -$104.47M-84.1% | -$72.19M-16.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s revenue?
- ARS Pharmaceuticals, Inc. (SPRY) generated $99.0M in revenue over the trailing twelve months, up 1.9% year over year.
- Is ARS Pharmaceuticals, Inc. profitable?
- ARS Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $198.0M over the trailing twelve months, a -200.0% net margin.
- What is ARS Pharmaceuticals, Inc.'s earnings per share?
- ARS Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.01.
- Where does ARS Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
